We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

271 hedge funds and large institutions have $4.27B invested in Bio-Rad Laboratories Class A in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 81 increasing their positions, 119 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more call options, than puts

Call options by funds: $2.8M | Put options by funds: $1.29M

1.45% more ownership

Funds ownership: 76.8%78.25% (+1.4%)

0% more capital invested

Capital invested by funds: $4.26B → $4.27B (+$9.01M)

9% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 33

2% less funds holding

Funds holding: 276271 (-5)

32% less repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 119

40% less funds holding in top 10

Funds holding in top 10: 106 (-4)

Holders
271
Holders Change
-5
Holders Change %
-1.81%
% of All Funds
6.76%
Holding in Top 10
6
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-40%
% of All Funds
0.15%
New
30
Increased
81
Reduced
119
Closed
33
Calls
$2.8M
Puts
$1.29M
Net Calls
+$1.51M
Net Calls Change
+$1.44M
Name Holding Trade Value Shares
Change
Change in
Stake
Jane Street
276
Jane Street
New York
-$2.23M -9,835 Closed
CS
277
Candriam SCA
Luxembourg
-$2.15M -9,500 Closed
EI
278
EAM Investors
California
-$2.13M -9,424 Closed
Tudor Investment Corp
279
Tudor Investment Corp
Connecticut
-$2.04M -9,000 Closed
LCM
280
Laurion Capital Management
New York
-$1.49M -6,572 Closed
Rafferty Asset Management
281
Rafferty Asset Management
New York
-$819K -3,618 Closed
UFF
282
USA Financial Formulas
Michigan
-$782K -3,455 Closed
SCM
283
Stevens Capital Management
Pennsylvania
-$740K -3,272 Closed
OAM
284
Oxford Asset Management
United Kingdom
-$728K -3,217 Closed
CANY
285
Caxton Associates (New York)
New York
-$657K -2,903 Closed
SCP
286
Syntal Capital Partners
Texas
-$579 -2,560 Closed
EMG
287
Ellington Management Group
Connecticut
-$475K -2,100 Closed
HCM
288
Highbridge Capital Management
New York
-$435K -1,932 Closed
IR
289
Invictus RG
Bermuda
-$401K -1,774 Closed
Balyasny Asset Management
290
Balyasny Asset Management
Illinois
-$372K -1,644 Closed
DTL
291
Dynamic Technology Lab
Singapore
-$366K -1,618 Closed
TI
292
Trexquant Investment
Connecticut
-$308K -1,362 Closed
GCP
293
GSA Capital Partners
United Kingdom
-$297K -1,314 Closed
PM
294
Parametrica Management
Hong Kong
-$291K -1,288 Closed
OTPPB
295
Ontario Teachers' Pension Plan Board
Ontario, Canada
-$271K -1,198 Closed
Marshall Wace
296
Marshall Wace
United Kingdom
-$252K -1,114 Closed
JMPWA
297
JP Morgan Private Wealth Advisors
California
-$242K -1,070 Closed
CM
298
Corvex Management
New York
-$226K -1,000 Closed
AIM
299
Assured Investment Management
New York
-$217K -960 Closed
CCM
300
Cohen Capital Management
California
-$204K -900 Closed

BIO Hedge Fund Activity: Q3 2017 in Review

271 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2017, worth a combined $4.27B — up 0.21% from $4.26B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of BIO and 30 opened new positions — a net loss of 3 holders — while 119 trimmed existing stakes and 81 added.

The largest buyer was American Century Companies, opening a new position worth an estimated $127M. The largest seller was Fidelity Investments, cutting an estimated $124M.

  • 271 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2017, down from 276 in Q2 2017.
  • Funds reported $4.27B of Bio-Rad Laboratories Class A stock for Q3 2017, up 0.21% quarter-over-quarter.
  • 30 funds opened new Bio-Rad Laboratories Class A positions in Q3 2017 and 33 closed out, a net change of -3 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q3 2017 was American Century Companies, an estimated $127M added.
  • The largest Bio-Rad Laboratories Class A seller in Q3 2017 was Fidelity Investments, an estimated $124M sold.

Based on aggregated 13F filings for Q3 2017.